Within the HER2-positive tumors, the prevalence of PIK3CA mutations (19%) is comparable to results from neoadjuvant trials in the HER2-positive BC population, ranging from 19.2% to 24.3% [18, 19, 34]. This evidence concerns the gene PIK3CA and breast cancer.